Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Alex Spira"'
1
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer
Autor: D. Ross Camidge, Fabrice Barlesi, Jonathan W. Goldman, Daniel Morgensztern, Rebecca Heist, Everett Vokes, Alex Spira, Eric Angevin, Wu-Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly
Publikováno v: Journal of Clinical Oncology. 41:1105-1115
PURPOSE Overexpression of c-Met protein and epidermal growth factor receptor ( EGFR) mutations can co-occur in non–small-cell lung cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class ant
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e2431abacc3768c259b0162a08fda6
https://doi.org/10.1200/jco.22.00739
Zobrazit plný text záznamu
5
Abstract CT127: A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non-small cell lung cancer
Autor: Melissa Johnson, Jason Henry, Alex Spira, James Battiste, Iyad Alnahhas, Manmeet Ahluwalia, Minal Barve, Jeffrey Edenfield, DoHyun Nam, Sudharshan Eathiraj, Julio Hajdenberg, Sergey Yurasov, Helena Yu, Patrick Wen
Publikováno v: Cancer Research. 83:CT127-CT127
Background: The epidermal growth factor receptor (EGFR) is a potent oncogene commonly altered in many cancers, including glioblastoma (GBM) and non-small cell lung cancer (NSCLC). EGFR tyrosine kinase activity driven by common EGFR mutations can be i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5072cee0568d5b831332258ada2c47c5
https://doi.org/10.1158/1538-7445.am2023-ct127
Zobrazit plný text záznamu
6
Abstract CT173: A phase 1, open-label, multicenter, dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced solid tumors
Autor: Jason T. Henry, Douglas Orr, Atrayee Basu-Mallick, Alex Spira, Christine Lihou, Neelesh Sharma, Peggy Scherle, Rachel Chiaverelli, Manish R. Patel
Publikováno v: Cancer Research. 83:CT173-CT173
Background: CDK9 is a key regulator of transcription elongation and recent studies suggest selective CDK9 inhibition may be a promising approach to treat “transcription-addicted” cancers that are dependent on oncogenic drivers with a short half-l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf25358cc989a0f43ff2df5525103c08
https://doi.org/10.1158/1538-7445.am2023-ct173
Zobrazit plný text záznamu
7
Akademický článek
Classifying early infant feeding status from clinical notes using natural language processing and machine learning
Autor: Dominick J. Lemas, Xinsong Du, Masoud Rouhizadeh, Braeden Lewis, Simon Frank, Lauren Wright, Alex Spirache, Lisa Gonzalez, Ryan Cheves, Marina Magalhães, Ruben Zapata, Rahul Reddy, Ke Xu, Leslie Parker, Chris Harle, Bridget Young, Adetola Louis-Jaques, Bouri Zhang, Lindsay Thompson, William R. Hogan, François Modave
Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The objective of this study is to develop and evaluate natural language processing (NLP) and machine learning models to predict infant feeding status from clinical notes in the Epic electronic health records system. The primary outcome was t
Externí odkaz: https://doaj.org/article/c74f56066a6144a0982acae63e3c3295
Zobrazit plný text záznamu
8
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer
Autor: Davey B. Daniel, Luis Paz-Ares, Mustafa Ozguroglu, Corinne Faivre-Finn, Scott J. Antonia, David R. Spigel, Phillip A. Dennis, Corey J. Langer, Cathy O'Brien, David Planchard, Shuji Murakami, David Vicente, Anna Rydén, Y. Zhang, Marina Chiara Garassino, Suresh Senan, Rina Hui, Alex Spira
Publikováno v: Future Oncology, 17(10), 1165-1184. Future Medicine Ltd.
Garassino, M C, Paz-Ares, L, Hui, R, Faivre-Finn, C, Spira, A, Planchard, D, Ozguroglu, M, Daniel, D, Vicente, D, Murakami, S, Langer, C, Senan, S, Spigel, D, Ryden, A, Zhang, Y, O'Brien, C, Dennis, P A & Antonia, S J 2021, ' Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer ', Future Oncology, vol. 17, no. 10, pp. 1165-1184 . https://doi.org/10.2217/fon-2020-1102
Garassino, M C, Paz-Ares, L, Hui, R, Faivre-Finn, C, Spira, A, Planchard, D, Özgüroğlu, M, Daniel, D, Vicente, D, Murakami, S, Langer, C, Senan, S, Spigel, D, Rydén, A, Zhang, Y, O'Brien, C, Dennis, P A & Antonia, S J 2021, ' Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer ', Future Oncology, vol. 17, no. 10, pp. 1165-1184 . https://doi.org/10.2217/fon-2020-1102
Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus pla
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8996710d39bff8fe354388b7492bdc5b
https://research.vumc.nl/en/publications/c03a6381-5105-41ae-bdc3-fef7664d188b
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje